Ionpath develops MIBI (Multiplexed Ion Beam Imaging) technology for high-definition spatial proteomics. Its platform provides highly multiplexed, quantitative protein imaging with sensitivity and true subcellular resolution down to 350 nm. The company sells MIBIscope instruments and offers end-to-end Spatial Proteomics Services to translational and clinical researchers. Customers include pharmaceutical, biotechnology, and research organizations working in immuno-oncology, immunology, neuroscience, and infectious disease research. Ionpath says its technology delivers the throughput and reproducibility required for clinical studies. The company plans to scale its organization to support increasing demand and to accelerate development efforts in collaboration with strategic partners. IONpath develops high-definition spatial proteomics and a multiplexed ion beam imaging (MIBI) platform to enable deeper understanding of the tissue microenvironment. Its technology provides multiplexed, quantitative single-cell analysis for tissue imaging and analysis. The company combines MIBI technology with pathology and data-science expertise to deliver actionable insights to translational and clinical researchers. Target users include pharmaceutical, biotechnology, and research organizations working in immuno-oncology, immunology, neuroscience, and infectious disease research. Led by CEO Sander Gubbens, PhD, IONpath aims to accelerate medical discovery and improve human health. The company planned to use the Series B proceeds to continue expanding operations and its business reach.

Total raised

$18M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2020